Replies to post #131878 on Biotech Values

[Orangenation5]

The question to ask, however, is whether it ought to be updated. Based on the thinking in #msg-69330570, I’m inclined to say that the answer is no.

Just looking for clarification of this important point.

Are you basically of the opinion that other companies should just give up on their nuke programs because PSI-7977 just can't be beat?

Also, I think it makes sense to want to pair your own PI/other with PSI-7977 being it is the current leader, however if a company has the capability to assess its own all-oral, why not take advantage of that - and if successful - they can play the pricing game and get 100% of the profits rather than sharing with GILD.

Thanks!

PS - I'm a newbie poster, but browse often.